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Allergic diseases such as bronchial asthma and atopic dermatitis develop by a combination of genetic and environmental factors. Several candidate 
causative genes of asthma and atopy have been reported as the genetic factors. The clinical features of patients and causes of diseases vary. There-
fore, personalized medicine (tailor-made medicine) is necessary for the improvement of quality of life (QOL) and for asthma cure. Pharmacogenetics 
is very important for personalized medicine. Here, we present the genetics and pharmacogenetics of asthma in children. Finally, we show the guide-
line for personalized medicine for asthma, particularly in childhood, including the pharmacogenetics of anti-asthmatic drugs, preliminarily produced 
by the authors.
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INTRODUCTION
Allergic diseases such as bronchial asthma and atopic derma-
titis develop as a result of a combination of genetic and envi-
ronmental factors. Several candidate causative genes of asthma 
and atopy have been reported as the genetic factors.
Recently treatment/management guidelines on bronchial 
asthma and many other disorders have been published, and 
they are used in clinical practice. However, the clinical features 
of patients and causes of diseases vary. Therefore, personalized 
medicine (tailor-made medicine) is necessary for the improve-
ment of quality of life (QOL) and for asthma cure. Pharmacoge-
netics is very important for personalized medicine.
Here, we present the genetics and pharmacogenetics of asth-
ma in children.
GENETIC PREDISPOSITION TO DEVELOPMENT OF 
ASTHMA AND ATOPY
There is sufficient evidence to indicate that asthma is heredi-
tary. A number of studies have shown an increased prevalence 
of asthma and the phenotype associated with asthma among 
the offspring of subjects with asthma compared with the off-
spring of subjects without asthma.
Many studies have shown that there is a genetic accumulation 
in the development of asthma and allergic disorders. Therefore, 
the development of asthma and allergic disorders is correlated 
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with some genes. We consider that multiple causative genes are 
involved, and not a single gene, because there are multiple 
pathogeneses of asthma and allergic reactions.
GENES RELATED TO DEVELOPMENT OF ASTHMA AND 
ATOPY
Many candidate genes related to the development of asthma 
and atopy have been identified, and different genes may be in-
volved in different ethnic groups.
1 Among more than 100 genes 
determined from candidate gene association studies, 79 genes 
are associated with an asthma- or atopy-related phenotype in 2 
or more independent study samples.
2
Next, we focus on the several genes related to the develop-
ment of asthma and atopy, in accordance with the various stag-
es of allergic reaction and development of asthma and atopy.
HLA genes and asthma
HLA genes have been reported to be associated with bronchi-
al asthma.
3 Moreover, a relationship between the severity of 
childhood asthma and HLA type has been reported.
4
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Genetic variation of cytokine signaling in atopy, and enhanced 
IgE production
IgE production is upregulated by Th2 cytokines, particularly 
interleukin-4 (IL-4), and is downregulated by Th1 cytokines, 
particularly interferon-g (IFN-g). Interleukin-12 (IL-12) and in-
terleukin-18 (IL-18) are the cytokines that induce IFN-g and 
downregulate IgE production.
5 We review the genetic variation 
of the cytokine signaling in atopy, and enhanced IgE production.
This item is divided into two parts, (i) “Genes related to upregu-
lation of IgE production in asthma and atopy” and (ii) “Genes re-
lated to downregulation of IgE production in asthma and atopy.”
Genes related to upregulation of IgE production in asthma and 
atopy
Several linkage analyses and mutations of candidate genes of 
atopy (i.e., enhanced IgE production) have been reported. In 
1989, Cookson et al.
6 reported a linkage between IgE responses 
underlying asthma and rhinitis and chromosome 11q. More-
over, Shirakawa et al.
7 reported that a common variant of FceRIb 
on chromosome 11, Ile181Leu within the 4th transmembrane 
domain, shows significant association with positive IgE respons-
es. Several associations have been noted between atopy and 
genes on the chromosome 5 cytokine cluster, including IL-4.
An Ile50Val (numbering for mature peptide) variant of human 
IL-4Ra has been identified. In 1998, Mitsuyasu et al.
8 reported 
that the Ile50Val variant of the IL-4Ra chain upregulates IgE 
synthesis and is associated with atopic asthma. Ile50 is associ-
ated with atopic asthma but not with nonatopic asthma; Ile50 
is specifically and significantly associated with increased total 
serum IgE levels and mite-specific IgE. The association with at-
opy was particulary strong in children.
8 The data from both 
mouse and human cell lines strongly suggest that the Ile50 vari-
ant of IL-4Ra significantly upregulates receptor response to IL-
4, with a resultant increased activation of Stat6, and hence, in-
creased cell proliferation and increased IgE production. More-
over, Shirakawa et al.
9 noted genetic variants of IL-13.
Genes related to downregulation of IgE production in asthma 
and atopy
The genetic defects in the downregulation (brake) of IgE pro-
duction, particularly in terms of IL-12 and IL-18 signalings, are 
discussed. We found that the reduced IFN-g production by pe-
ripheral blood mononuclear cells (PBMCs) following stimula-
tion with IL-12 or IL-18 is associated with heterozygous IL-12 
receptor b2 (IL-12Rb2) chain gene mutations (2496 del 91, 1577 
A to G (Arg 313 Gly), 2799 A to G (His 720 Arg) or IL-18 receptor 
a (IL-18Ra) chain gene mutation (del 950 CAG) in atopic sub-
jects.
10,11
We identified a novel heterozygous single-nucleotide substi-
tution 1400 T to C (Leu 467 Pro), in the seventh exon of the IFN-
g receptor 1 (IFN-gR1) chain gene.
12 This substitution was de-
tected in six of 89 allergic patients (including asthma), but not 
in 72 nonallergic subjects. There was a difference in the Leu 467 
Pro frequency between allergic and nonallergic subjects 
(P<0.05). The serum IgE levels of the allergic patients with the 
Leu 467 Pro substitution were higher than those of the nonal-
lergic subjects (P<0.001). These results suggest that Leu 467 Pro 
in the IFN-gR1 chain gene is one of the candidate susceptibility 
genes for asthma or atopic diseases.
Genetic variation of mediators and other molecules in asthma 
and atopy
LTC4S and asthma
The locus of leukotriene C4 synthase (LTC4S) is on chromo-
some 5q35 and has been associated with allergic diseases on 
the basis of a genomewide search. Cysteiny1 leukotrienes 
(cysLTs) play important roles in asthma and can mediate bron-
chial smooth muscle constriction and increase mucous secre-
tion, vascular permeability, and cellular infiltration.
13 LTC4S 
converts LTA4 to LTC4 by conjugation to reduced glutathione. A 
single-nucleotide promoter polymorphism (A-444C) in LTC4S 
has been associated with aspirin-sensitive asthma,
14,15 although 
recent studies have found no association between this promot-
er polymorphism and aspirin-sensitive asthma.
16
Very recently, we have reported that a novel single-nucleotide 
substitution 10G>A (Glu 4 Lys) in LTC4S is associated with asth-
ma.
17
nNOS and asthma
Nitric oxide (NO) is produced by a group of enzymes referred to 
as nitric oxide synthase: endothelial (eNOS), neuronal (nNOS), 
and inducible NOS (iNOS). The association of some nNOS 
markers with asthma or related phenotypes has been reported.
18
Genetic defects in target organs in asthma and atopy
ADRb2 and asthma
There was no relationship between b2-adrenergic receptor 
(ADRb2) polymorphisms and asthma prevalence, but the Gly-
16 variant was apparently associated with a more severe form 
of asthma.
19 Subsequently, Turki et al.
20 found that the Gly-16 
allele is more frequent among subjects with nocturnal asthma 
than among nonnocturnal asthmatics.
ADAM33 and asthma
Van Eerdewegh and Holgate et al.
21 performed a genomewide 
scan on 460 Caucasian families and identified a locus on chro-
mosome 20p13 that is linked to asthma (Log10 of the likelihood 
ratio LOD, 2.94) and bronchial hyperresponsiveness (LOD, 
3.93). A survey of 135 polymorphisms in 23 genes identified the 
ADAM33 gene as being significantly associated with asthma 
using case control, transmission disequilibrium and haplotype 
analyses (P=0.04-0.000003). ADAM proteins are membrane-
anchored metalloproteases with diverse functions, which in-
clude the shedding of cell-surface proteins such as cytokines Allergy Asthma Immunol Res. 2010 January;2(1):14-19.  doi: 10.4168/aair.2010.2.1.14
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and cytokine receptors. The identification and characterization 
of ADAM33, a putative asthma susceptibility gene identified by 
positional cloning in an outbred population, should provide in-
sights into the pathogenesis and natural history of this com-
mon disease.
GENETIC CLASSIFICATION OF ATOPY AND ASTHMA
On the basis of many reports and our results, we present a 
new genetic classification of atopy and asthma in Fig. 1.
22 There 
are four categories of genes that control the expression of aller-
gic disorders, which include (i) antigen recognition, (ii) IgE pro-
duction (downregulation=brake, and upregulation), (iii) pro-
duction and release of mediators, and (iv) events on target or-
gans. This genetic classification will facilitate the development 
of pharmacogenetics and personalized medicine.
PHARMACOGENETICS OF ASTHMA
The response of an individual patient to any given drug de-
pends on several factors such as pathogenesis of disease, com-
pliance, disease severity, and genetic background.
23 The great 
hope in pharmacogenetics is that it will help predict either 
treatment response (efficacy) or the risk of adverse drug reac-
tions in the general population and that it will prove cost-effec-
tive to genotype individuals before treatment,
23 that is, for per-
sonalized medicine (tailor-made medicine). Here, we review 
the pharmacogenetics of anti-asthmatic drugs.
Pharmacogenetics of b2-agonists
Beta2-agonists act via binding to the b2-adrenergic receptor 
(ADRb2), that is, a cell surface G-protein-coupled receptor. The 
b2-adrenergic receptor has several polymorphisms in the cod-
ing region, such as Arg 16 Gly, Gln 27 Glu, and Thr 164 ILe. The 
Arg 16 Gly and Gln 27 Glu are functionally important. Patients 
with homozygous for Arg 16 did worse clinically in terms of the 
major end points and showed adverse effects, rather than ho-
mozygous for Gly 16.
24-26
Pharmacogenetics of leukotriene antagonists
Leukotrienes are very important mediators in asthma in chil-
dren as well as in adults. Leukotrienes are released by eosino-
phils, mast cells, and alveolar macrophages. In the production of 
leukotrienes, several enzymes such as 5-lipoxygenase (ALOX5) 
and leukotriene C4 synthase (LTC4S) are important. LTC4S is a 
membrane-bound glutathione transferase, and synthesizes cys-
teinyl-leukotrienes, converting LTA4 to LTC4.
In the treatment with zafirlukast (one of the leukotriene re-
ceptor antagonists), patients with the homozygous for A-444 
showed a lower FEV1 response than those with the A/C or C/C 
genotype.
27
Moreover, treatment with leukotriene receptor antagonists 
(montelukast or pranlukast) was more effective on adult or pe-
diatric patients with the A/C or C/C genotype at position-444 
(LTC4S-444) than on those with the A/A genotype.
28,29
Fig. 2. Management of personalized medicine (tailor-made medicine) for asthma.
Diagnosis of bronchial asthma
(It usually depends on a guideline)
Allergens diagnosis,
risk factors diagnosis
  (It usually depends on a guideline)
A judgment of the disease severity
of the bronchial asthma
  (It usually depends on a guideline)
Intermittent Mild Moderate Severe
Tailor-made management Medicine choice for tailor-made treatment
Markers for tailor-made treatment
medicine choice
□  DSCG
□  histamine H1 antagonists
□  leukotriene receptor antagonists
□  Th2 cytokine inhibitor
□  b2 stimulants
□  Xanthine
□  Inhaled corticosteroids
Avoiding allergens
mite, house dust, cedar, candida,
dog, cat, egg, milk, soy bean, etc
respiratory infection by viruses,
outdoor air pollution,
room air pollution,
passive smoking, and smoking
food and food additives,
parasitic infection,
exercise and hyperventilation,
the weather
drugs, others
Avoiding risk factors
Tailor-made management
for food allergy
(various symptoms such as rash)
(1) symptoms
(2) laboratory findings
(3) genetic polymorphisms, mutations
       (pharmacogenetics)
Fig. 1. A new genetic classification of asthma and atopy.
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IFN-γR1
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    IL-13
    VDJ-Cε
    FcεRIβ
(3)  mediators
         production
(4)  target organ
Th1 Th2
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IL-4 IL-13
DH
IgG
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IgA
IgE
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APC
helper
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Pharmacogenetics of a Th2 cytokine inhibitor
Suplatast tosilate is a Th2 cytokine inhibitor.
30 In our recent 
study, treatment with suplatast tosilate was more effective in 
children without the -444 A/C polymorphism of the LTC4S 
gene, and in children without the IL-13 variant Arg 110 Gln. In 
children who responded well, IFN-g production was signifi-
cantly increased after treatment.
Pharmacogenetics of corticosteroids
Inhaled corticosteroids (ICS) are very effective for asthma in 
children as well as adults. However, there are patients with se-
vere asthma who show no response to treatment with ICS. 
There are reports concerning the pharmacogenetics of cortico-
steroids. The IL-4 589T allele (589 C/T SNP) was found to be as-
sociated with ICS-resistant asthma.
31,32 The TBX21 (T-bet) gene 
(His 33 Gln) and the corticotropin-releasing hormore receptor 
1 (CRHR1) gene are important for the pharmacogenetics of 
ICS.
33 Particularly in Caucasian children, the heterozygous 
TBX21 33 His/Gln individuals demonstrated a marked im-
provement in airway hyperresponsiveness compared with 33 
His/His homozyotes on ICS therapy.
33,34
PERSONALIZED MEDICINE (TAILOR-MADE MEDICINE) 
FOR ASTHMA IN CHILDHOOD
The clinical features of patients and causes of diseases vary. 
Therefore, personalized medicine is necessary for the improve-
ment of QOL and for asthma cure. Pharmacogenetics is very 
important for personalized medicine. Here, we show the guide-
line for personalized medicine for asthma, particularly in chil-
DSCG
H1-
antagonists
LTRA
Th2 cytokine 
inhibitor 
long-acting 
theophylline
b2 agonists ICS
effective effective effective effective (side effect) effective (non-effective) effective
(1)  Symptoms and clinical findings
        viral infection ○
        exrecise induced asthma ○ ○ ○
        asprin induced asthma ○ ○
        complicated with allergic rhinitis ○
        complicated with atopic dermatitis ○
(2)  Laboratory findings
        reduced No. of eosinophil or basophil
           in peripheral blood
○
        reduced production of IFN-g ○
        increased LT level in urine  ○
        reduced expression of CysLT1R in eosinophil 
        (less than 60%)
○
(3)  Gene polymorphisms and mutations (Pharmacogenetics)
        LTC4S   A-444C   (AA) ○
        LTC4S   A-444C   (AC or CC) ○
        IL-13   R110Q   (R) ○
        ALOX5   (rs2115819 GG) ○
        MRP1   (rs119774 CT) ○
        CYP1A2   -3594(GT) ○
        ADRb2   R16G (R) （○）
        TBX21   (T-bet)   H33Q   (H/Q or Q/Q) ○
        CRHR1   (rs1876828) ○
Fig. 3.  Medicine choice for personalized medicine based on the symptoms, laboratory findings and pharmacogenetics.
○: positive markers; (○): possible markers.
DSCG, disodium cromoglycate; H1-antagonists, histamine H1-receptor antagonists; LTRA, leukotriene receptor antagonists; ICS, inhaled corticosteroids; LT, leukotri-
ene; LTC4S, leukotriene C4 synthase; ALOX5, 5-lipoxygenase; MRP1, Multidrug resistance-associated protein 1; ADRb2, b2-aderenergic receptor; CRHR1, corticotro-
pin-receptor 1 releasing hormone; R, Arginine; G, Glycine; H, Histidine; Q, Glutamine.Allergy Asthma Immunol Res. 2010 January;2(1):14-19.  doi: 10.4168/aair.2010.2.1.14
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dren, including the pharmacogenetics of anti-asthmatic drugs, 
preliminarily produced by the authors (Figs. 2, 3).
Asthma develops by a combination of genetic and environ-
mental factors. There are many environmental factors such as 
allergens (house dust, mites, foods, and pets so on), viral infec-
tions, exercise, passive smoking, and air pollution. The environ-
mental factors are different for each patient. Therefore, it is very 
important to first eliminate each environmental factor for each 
patient and to take preventive measures against each environ-
mental factor (Fig. 2), that is, the personalized preventive mea-
sures. The preliminary guideline for personalized medicine 
(tailor-made medicine) for asthma has been published, on the 
basis of various clinical symptoms, various laboratory findings, 
as well as pharmacogenetics of anti-asthmatic drugs.
Figure 3 shows the guideline for personalized medicine. For 
example, as one of the markers of symptoms, for viral-induced 
asthma, leukotriene receptor antagonists are effective. For exer-
cise induced asthma, disodium cromoglycate (DSCG), leukotri-
ene receptor antagonists, or b2-agonists are effective. As one of 
the laboratory findings, in the patients with poor IFN-g produc-
tion, Th2 cytokine inhibitor is effective. As one of the gene mark-
ers, in LTC4S-444 A/A type, Th2 cytokine inhibitor is effective, 
and in LTC4S-444 A/C or C/C type, leukotriene receptor antag-
onists are effective. In TBX21 (T-bet) 33 His/Gln or Gln/Gln, ICS 
is effective.
In the near future, the guidelines for the personalized medi-
cine (tailor-made medicine) for asthma will become more 
available. For personalized medicine, it is necessary for us to 
obtain both the approval of an ethical committee and informed 
consent.
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